Personal information
Biography
Biography
Since November 2020: Chief Scientific Officer at Intravacc BV, Bilthoven, the Netherlands.
Since January 2022 also registered qualified Person at Intravacc BV
Since May 2013: Registered Responsible Person (RP) of Tumor Tissue Bank - The Netherlands (TTB-NL)
Since May 2015: Registered Qualified Person (QP), GMP-facility ERC-The Netherlands.
Since January 2013 visiting professor at Strathclyde University Glasgow UK, continued on January 2023.
Since May 1, 2011 Chief Scientific Officer at Epitopoietic Research Corporation (ERC), Isnes, Belgium, a clinical stage company, which develops a specific immunotherapy against brain cancer. Since January 2008: Special professor Immune Intervention, Wageningen University, the Netherlands. Wageningen Universiteit en Research Centrum. Celbiologie en Immunologie (CBI) group. Since July 2002: Special Professor (= adjunct) in Immunology and Virology at North Carolina State University (NCSU), Raleigh. Department of Population Health and Pathobiology.
Research Interest
Dr. Schijns’s research interest is focused on modeling and optimizing of immune reactions and improving the patient’s immune defense. He is interested in strategies for activating of the immune system, for both, the induction of specific immunity and for the training of innate immunity. This involves administration of properly chosen immune signals delivered in a strict time-related order. Dr. Schijns’s recent research interest includes immunomodulation by targeting naturally occurring inhibitors of the developing immune reaction. Based on the knowledge of immune responses initiation steps, new vaccines and immune strengthening strategies can be designed in a rational way that can be used in veterinary species and in humans.